NB
Therapeutic Areas
Sanara MedTech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CellerateRX® Gel | Surgical/Wound Management | Approved |
| CellerateRX® Surgical Powder | Surgical/Wound Management | Approved |
| BIASURGE® Advanced Surgical Solution | Surgical Irrigation | Approved |
| FORTIFY TRG® Tissue Repair Graft | Soft Tissue Repair | Approved |
| FORTIFY FLOWABLE® Extracellular Matrix | Soft Tissue Repair | Approved |
| TEXAGEN® Amniotic Membrane Allograft | Wound and Tissue Repair | Approved |
| ALLOCYTE® Plus Advanced Viable Bone Matrix | Bone Grafting | Approved |
| BiFORM® Bioactive Moldable Matrix | Bone Void Filling | Approved |
Leadership Team at Sanara MedTech
RB
Robert Bearden
Senior Vice President, Clinical and Medical Affairs
NG
Nicholas Gachassin, III
General Counsel
TP
Tyler Palmer
Chief Corporate Development and Strategy Officer
BD
Bob DeSutter
Director
RM
Roszell Mack III
Director
EM
Eric Major
Director